Detalhe da pesquisa
1.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Lancet Oncol
; 25(1): 117-125, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092009
2.
Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma.
Ann Hematol
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730207
3.
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
Ann Hematol
; 103(6): 1989-2001, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233570
4.
A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.
J Korean Med Sci
; 39(2): e5, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38225781
5.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Mol Cancer
; 22(1): 200, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066564
6.
The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Biochem Biophys Res Commun
; 673: 36-43, 2023 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356143
7.
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Am J Gastroenterol
; 118(8): 1373-1380, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36728217
8.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Haematologica
; 108(3): 811-821, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200417
9.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171597
10.
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
Mod Pathol
; 35(4): 480-488, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34764434
11.
Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
Blood
; 136(22): 2548-2556, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32584959
12.
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Ann Hematol
; 101(6): 1217-1226, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445844
13.
A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum ß2-microglobulin levels.
Br J Haematol
; 193(2): 307-315, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216979
14.
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Ann Hematol
; 100(10): 2529-2539, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304287
15.
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Eur Radiol
; 31(1): 152-162, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809165
16.
Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09).
Ann Hematol
; 99(12): 2831-2836, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32989495
17.
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Ann Hematol
; 99(6): 1283-1291, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32333154
18.
A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma.
Ann Hematol
; 99(2): 255-264, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31897676
19.
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
Ann Hematol
; 99(2): 309-319, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872360
20.
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Am J Hematol
; 95(4): 413-421, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31919872